- Home
- MULN vs CHRO Comparison
MULN vs CHRO Comparison
Compare MULN & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MULN
- CHRO
- Stock Information
- Founded
- MULN 2014
- CHRO 2002
- Country
- MULN United States
- CHRO United States
- Employees
- MULN N/A
- CHRO N/A
- Industry
- MULN Auto Manufacturing
- CHRO
- Sector
- MULN Consumer Discretionary
- CHRO
- Exchange
- MULN Nasdaq
- CHRO Nasdaq
- Market Cap
- MULN 3.5M
- CHRO 3.8M
- IPO Year
- MULN N/A
- CHRO 2024
- Fundamental
- Price
- MULN $0.48
- CHRO $1.90
- Analyst Decision
- MULN
- CHRO Strong Buy
- Analyst Count
- MULN 0
- CHRO 1
- Target Price
- MULN N/A
- CHRO N/A
- AVG Volume (30 Days)
- MULN 10.5M
- CHRO 855.2K
- Earning Date
- MULN 02-11-2025
- CHRO 02-20-2025
- Dividend Yield
- MULN N/A
- CHRO N/A
- EPS Growth
- MULN N/A
- CHRO N/A
- EPS
- MULN N/A
- CHRO N/A
- Revenue
- MULN $156,570.00
- CHRO N/A
- Revenue This Year
- MULN N/A
- CHRO N/A
- Revenue Next Year
- MULN N/A
- CHRO N/A
- P/E Ratio
- MULN N/A
- CHRO N/A
- Revenue Growth
- MULN N/A
- CHRO N/A
- 52 Week Low
- MULN $0.36
- CHRO $0.45
- 52 Week High
- MULN $987.00
- CHRO $6.00
- Technical
- Relative Strength Index (RSI)
- MULN 25.48
- CHRO 86.63
- Support Level
- MULN $0.36
- CHRO $0.81
- Resistance Level
- MULN $0.54
- CHRO $1.10
- Average True Range (ATR)
- MULN 0.17
- CHRO 0.26
- MACD
- MULN 0.02
- CHRO 0.08
- Stochastic Oscillator
- MULN 10.82
- CHRO 70.64
About MULN Mullen Automotive Inc.
Mullen Automotive Inc is engaged in manufacturing electric vehicles and energy solutions. The company strives to make electric vehicles more accessible by building an end-to-end ecosystem that takes care of all aspects of electric vehicle ownership. The Company owns and partners with several synergistic businesses, all working towards the same goal of creating clean and scalable electric vehicles and energy solutions. The company has two segments Bollinger and Mullen/ELMS, which generates revenue.
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.